Mobile medical apps guidance: what's good for the US is good for the EU
This article was originally published in SRA
Bradley Merrill Thompson and Erik Vollebregt argue that draft guidance from the US Food and Drug Administration on mobile medical applications could apply in the EU too.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.